Bringing the Oncology Community Together
FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors
The FDA has approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.
Read More >>
From Bedside to Bench
MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer
Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRC
Making Strides With Microspheres: Trial Aims to Extend SIR-Spheres Usage in CRC Liver Metastases
Proactively Managing Treatment-Related Adverse Events in Advanced Colorectal Cancer
FDA Approves Ramucirumab Plus Paclitaxel for Advanced Gastric Cancer
View More >>
- A Network of Your Peers
View more >>
Dr. Holcombe on the Utility of Stool DNA Test for Colon Cancer
Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel
Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETs
Most Popular Right Now
Tweets by @OncLive
New Metastatic Colorectal Cancer iPub
Insight from Fadi Braiteh, MD, and Robin Wachsman, RN, BS, OCN, CCRN, CBCN, on regorafenib in mCRC.
Treatment Considerations in Refractory CRC
Moderated by John L. Marshall, MD, this panel discussion includes expert perspectives from Johanna Bendell, MD, Marwan Fakih, MD, Heinz-Josef Lenz, MD, and Alan P. Venook, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.